Galderma Group AG
GALD.SWDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Next quarter
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Trifarotene | Phase 3 | Acne Vulgaris | - | - |
Nemolizumab | Phase 3 | Systemic Sclerosis | - | - |
CD07805/47 Gel | Phase 2 | Rosacea | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Galderma Group AG's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Galderma Group AG's (GALD.SW) pipeline across Phase 3, Phase 2. Its lead program is Trifarotene (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Galderma Group AG's next FDA catalyst?→
Galderma Group AG's (GALD.SW) next tracked catalyst is a Phase 3 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GALD.SW biotech catalysts?→
Add GALD.SW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Galderma Group AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.